This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The National Chlamydia Screening Programme (NCSP) that was implemented in England in 2008 to 2009 was compared with the same programme with increased screening coverage for men or with increased efficacy of partner notification.
Location/setting
UK/primary care.
Methods

Analytical approach:
The analysis was based on a mathematical model developed to estimate the costs and effects of the chlamydia screening programme. The authors stated that the perspective of the health care provider was taken.
Effectiveness data:
Most of the clinical and epidemiological data, such as the patient characteristics and the coverage rate, were from a report of the NCSP. Other official databases, such as the Vital Signs Index, were also used. The efficacy of partner notification was a key input for the model and was from a subgroup of the primary care trusts in which the NCSP was implemented.
Monetary benefit and utility valuations:
Not considered.
Measure of benefit:
The number of infections treated was the summary benefit measure.
Cost data:
The economic analysis was restricted to the costs of screening and partner notification. A breakdown of cost items was presented in an appendix. The cost of partner notification included the time for discussion of partner notification when notifying the patient or delivering the treatment, the provider referral by health professionals, and follow-up telephone calls. All economic inputs were estimated using data from the NCSP, for seven primary care trusts. Semi-structured interviews were conducted in 2008 to 2009 for the cost of partner notification. All costs were in UK pounds sterling (£).
Analysis of uncertainty:
Deterministic one-way sensitivity analyses were carried out to examine how robust the model findings were to variations in the partner notification costs, partner notification efficacy, and male screening coverage. The range of values for the cost per screening episode was based on available rates, while the other ranges were assumed by the authors.
Results
In the target population of three million men or women younger than 25 years old, the total costs were £46.26 million with the NCSP (24% of eligible women and 8% of eligible men screened; median of 0.4 partners notified per index case), £49.57 million with increased partner notification efficacy (from 0.4 to 0.8), and £69.17 million with increased screening coverage for men (from 8% to 24%).
The cost per infection treated was £506 (range 381 to 621) with the NCSP, £449 (range 345 to 545) with increased efficacy of notification, and £528 (range 397 to 648) with increased coverage for men.
The sensitivity analysis showed that increasing the cost of partner notification increased the cost per case treated linearly, but increased notification remained the most cost-effective option, in general, for reasonable cost values.
